The efficacy and safety profiles of GH therapy have led to the approval of GH use in many countries for the treatment of growth disorders, including GH deficiency (GHD) (3), idiopathic short stature (ISS) (3), Turner syndrome (TS), Prader-Willi syndrome (PWS), chronic renal failure (CRF), small for gestational age (SGA), and Noonan's Syndrome (4, 5). The gene discussed is GH1; the disease is SHOX-related short stature.